Frontline Treatment Decisions in Advanced or Metastatic Gastric/GEJ Adenocarcinoma
Audiocast Audiocast

Frontline Treatment Decisions in Advanced or Metastatic Gastric/GEJ Adenocarcinoma


Released:
7/31/19
Expires:
7/30/20
PDF:

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
7/31/19

Expires:
7/30/20

PDF:

Maximum Credits:
0.25
Audiocast Audiocast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
7/31/19
Expires:
7/30/20
PDF:


Maximum Credits:
0.25


Overview: In this audiocast, expert faculty explore treatment decisions for a patient with newly diagnosed metastatic gastric adenocarcinoma.

CME Information:

Faculty
Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Activity Planners
Amy Burdette, PhD
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Learning Objective
Upon completion, participants should be able to:

  • Develop treatment plans for patients with newly diagnosed advanced or metastatic gastric and GEJ cancer

Target Audience
This activity is intended for community oncologists.
 
Statement of Need
Knowledge related to the genetic nature of gastrointestinal (GI) cancers—specifically metastatic colorectal cancer (CRC), gastric and gastroesophageal junction (GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC)—as well as the use of biomarkers in patients with these cancers when appropriate, is rapidly evolving, requiring community oncologists to stay abreast of emerging evidence to guide treatment planning. Evidence-based guidelines and ongoing research can provide frameworks for determining treatment selection and proper sequencing across multitudes of different combinations of chemotherapy, molecular targeted therapies, anti-angiogenic agents, and immunotherapies; however, the most effective selection and sequence of agents continues to be debated. Focused, contextual education can help community oncologists better understand the role of factors such as patient characteristics and anatomical and molecular profiles of tumors in determining first-line treatment and subsequent lines of therapy.
 
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statement
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Instructions to Receive Credit
To receive credit, read the introductory CME material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: July 31, 2019
Expiration Date: July 30, 2020
Estimated Time to Complete This Activity: 15 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Johanna Bendell, MD, has indicated no real or apparent conflicts.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Copyright
© 2019 Med-IQ, Inc.

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.